Vitamin B6
Vitamin B6 , also called Pyridoxine , refers to a family of water
soluble substances - including pyridoxine, pyridoxal, and pyridoxamine, that are
closely related in form and function. Vitamin B6 is a water soluble nutrient that
cannot be stored in the body, but must be obtained daily from either dietary sources
or supplements.
Vitamin B6 is an important nutrient that supports more vital bodily functions
than any other vitamin. This is due to its role as a coenzyme involved in the metabolism
of carbohydrates, fats, and proteins. Vitamin B6 is also responsible for the manufacture
of hormones, red blood cells, neurotransmitters, enzymes and prostaglandins. Vitamin
B6 is required for the production of serotonin, a brain neurotransmitter that controls
our moods, appetite, sleep patterns, and sensitivity to pain. A deficiency of vitamin
B6 can quickly lead to insomnia and a profound malfunctioning of the central nervous
system.
Among its many benefits, vitamin B6 is recognized for helping to maintain healthy
immune system functions, for protecting the heart from cholesterol deposits, and
for preventing kidney stone formation. B6 is also effective in the treatment of
carpal tunnel syndrome, premenstrual syndrome, night leg cramps, allergies, asthma
and arthritis.
Common symptoms of vitamin B6 deficiency can include depression, vomiting, anemia,
kidney stones, dermatitis, lethargy and increased susceptibility to diseases due
to a weakened immune system. Infants suffering from vitamin B6 deficiency can be
anxious and irritable, and in extreme cases may develop convulsions.
Supplemental B6 is a commonly used as a treatment for nausea, morning sickness
and depression. Pregnant women have an increased need for supplemental vitamin B6,
as do patients suffering from heart disease or those undergoing radiation treatment.
Persons on high protein diets require extra vitamin B6, as do those taking antidepressants,
amphetamines, oral contraceptives, and estrogen.
Natural foods highest in vitamin B6 include brewers yeast, carrots, chicken,
eggs, fish, avocados, bananas, brown rice, and whole grains. The RDA for vitamin
B6 is 2 mg per day. Most B-complex formulas contain between 10 to 75 mg. of vitamin
B6.
Vitamin B6 is one of the few vitamins that can be toxic. Doses up to 500 mg per
day are uncommon but safe, but doses above 2 grams per day can lead to irreversible
neurological damage unless under the treatment of a physician. Vitamin B6 supplements
should not be taken by Parkinson's disease patients being treated with L-dopa as
vitamin B6 can diminish the effects of L-dopa in the brain.
VITAMIN B6 (PYRIDOXINE)
Click on the title to read the study Treatment of mild hyperhomocystinemia in
vascular disease patients A deficiency of vitamin B6 is a plausible molecular
basis of the retinopathy of patients with diabetes mellitus.
Effect of vitamin B6 on the side effects of a low-dose combined oral contraceptive.
Vitamin B6 in the treatment of the premenstrual syndrome - Review (1)
Effect of vitamin B-6 on plasma and red blood cell magnesium levels in premenopausal
women
Functional capacity of the tryptophan niacin pathway in the premenarchial
phase and in the menopausal age
Incident pain caused by collapsed vertebrae in menopause. The logical background
to a personal treatment protocol
Vitamins and metals: Potential dangers for the human being
Vitamin B6 status in cirrhotic patients in relation to apoenzyme of serum
alanine aminotransferase
Vitamin B6 concentrations in patients with chronic liver disease and hepatocellular
carcinoma
Abnormal vitamin B6 status in childhood leukemia.
Hyperhomocysteinaemia and end stage renal disease
Hyperhomocysteinemia confers an independent increased risk of atherosclerosis
in end-stage renal disease and is closely linked to plasma folate and pyridoxine
concentrations.
High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients.
The activities of coenzyme Q10 and vitamin B6 for immune responses.
Suppression of tumor growth and enhancement of immune status with high levels
of dietary vitamin B6 in BALB/c mice.
Homocysteine: Relation with ischemic vascular diseases.
A double blind study of vitamin B-sub-6 in Down's syndrome infants: I. Clinical
and biochemical results.
A double blind study of vitamin B-sub-6 in Down's syndrome infants: II. Cortical
auditory evoked potentials.
Long-term folic acid (but not pyridoxine) supplementation lowers elevated
plasma homocysteine level in chronic renal failure.
Prospects for nutritional control of hypertension
Unrecognized pandemic subclinical diabetes of the affluent nations: Causes,
cost and prevention
Vitamin and mineral deficiencies which may predispose to glucose intolerance
of pregnancy
Vitamin B6 alleviates the vascular complications of insulin-treated STZ-induced
diabetic rats
The endocrine pancreas in pyridoxine deficient rats.
Erythrocyte O2 transport and metabolism and effects of vitamin B6 therapy
in type II diabetes mellitus.
Tissue concentrations of water-soluble vitamins in normal and diabetic rats.
Malnutrition in geriatric patients: diagnostic and prognostic significance
of nutritional parameters.
Drug therapy during pregnancy.
Changes on levels of B6 vitamin and aminotransferase in the liver of diabetic
animals.
[Hemochromatotic cirrhosis complicating pyridoxine-sensitive hereditary sideroblastic
anemia. Case report]
[Vitamin status in diabetic neuropathy (thiamine, riboflavin, pyridoxin, cobalamin
and tocopherol)]
Failure of pyridoxine to improve glucose tolerance in diabetics.
Treatment of mild hyperhomocystinemia in vascular disease patients
Franken DG; Boers GH; Blom HJ; Trijbels FJ; Kloppenborg PW
Department of Medicine, University Hospital Nijmegen,
The Netherlands.
Arterioscler Thromb (U.S.) Mar 1994, 14 (3) p465-70.
Mild hyperhomocystinemia is recognized as a risk factor for premature arteriosclerotic
disease. A few vitamins and other substances have been reported to reduce blood
homocysteine levels, but normalization of elevated blood homocysteine concentrations
with any of these substances has not been reported. Therefore, we screened 421 patients
suffering from premature peripheral or cerebral occlusive arterial disease by oral
methionine loading tests for the presence of mild hyperhomocystinemia. Thirty-three
percent of patients with peripheral, and 20 percent of patients with cerebral occlusive
arterial disease, were identified with mild hyperhomocystinemia (14 percent of the
men, 34 percent of the premenopausal women, and 26 percent of the postmenopausal
women). Mildly hyperhomocystinemic patients were administered vitamin B6 250 mg
daily. After 6 weeks methionine loading tests were again assessed to evaluate the
effect of treatment. Patients with non-normalized homocysteine concentrations were
further treated with vitamin B6 250 mg daily and/or folic acid 5 mg daily and/or
betaine 6 g daily, solely or in any combination. Vitamin B6 treatment normalized
the afterload homocysteine concentration in 56 percent of the treated patients (71
percent of the men, 45 percent of the premenopausal women, and 88 percent of the
postmenopausal women). Further treatment resulted in a normalization of homocysteine
levels in 95 percent of the remaining cases. Thus, mild hyperhomocystinemia, which
is frequently encountered in patients with premature arteriosclerotic disease, can
be reduced to normal in virtually all cases by safe and simple treatment with vitamin
B6, folic acid and betaine, each of which is involved in methionine metabolism.
A deficiency of vitamin B6 is a plausible molecular basis of the retinopathy
of patients with diabetes mellitus.
Biochem Biophys Res Commun. 1991 Aug 30. 179(1). P 615-9
Eighteen patients with diabetes mellitus, some of whom had variously retinopathy,
pregnancy, and the carpal tunnel syndrome, and were variously treated with steroids
and vitamin B6, have been overviewed for periods of 8 months to 28 years. We have
established an association of a deficiency of vitamin B6 with diabetes by monitoring
the specific activity of the erythrocyte glutamic oxaloacetic transaminase and again
by the association with the carpal tunnel syndrome (C.T.S.). It has been known for
a decade that C.T.S. is caused by a B6 deficiency. The absence of retinopathy in
vitamin B6-treated diabetic patients over periods of 8 months - 28 years appears
monumental. These observations are like discovery and constitute a basis for a new
protocol to establish the apparent relationship of a deficiency of vitamin B6 as
a molecular cause of diabetic neuropathy. Blindness and vision are so important
that the strength or weakness of the observations are not important; the conduct
of a new protocol is important.
Articles about vitamins
|